<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317223</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_306</org_study_id>
    <nct_id>NCT03317223</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Triple Therapy With CJ-12420, Amoxicillin and Clarithromycin in H. Pylori Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to demonstrate the non-inferiority of CJ-12420-based triple&#xD;
      therapy (CJ-12420, amoxicillin and clarithromycin) versus lansoprazole-based triple therapy&#xD;
      (lansoprazole, amoxicillin and clarithromycin) in H. pylori eradication rate and to evaluate&#xD;
      the safety of CJ-12420 following oral administration of either triple therapy twice daily for&#xD;
      7 days in H. pylori positive patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, randomized, active controlled, phase 3 study. Subjects will be&#xD;
      randomly assigned to one of the two treatment groups (CJ-12420 50mg, lansoprazole 30mg). All&#xD;
      subjects will be asked to take 5 tablets include clarithromycin, amoxicillin twice a day for&#xD;
      7 days.&#xD;
&#xD;
      After the treatment, UBT test will be conducted to confirm the Helicobacter pylori&#xD;
      eradication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">January 24, 2019</completion_date>
  <primary_completion_date type="Actual">January 21, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rate</measure>
    <time_frame>twice a day</time_frame>
    <description>Subjects will be considered to succeed in achieving H. pylori eradication if subject's UBT test (Eradication Assessment)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>CJ-12420/Clarithromycin/Amoxicillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CJ-12420 50mg /Clarithromycin 500mg /Amoxicillin 1g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole/Clarithromycin/Amoxicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lansoprazole 30mg /Clarithromycin 500mg /Amoxicillin 1g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420/Clarithromycin/Amoxicillin</intervention_name>
    <description>CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days</description>
    <arm_group_label>CJ-12420/Clarithromycin/Amoxicillin</arm_group_label>
    <arm_group_label>Lansoprazole/Clarithromycin/Amoxicillin</arm_group_label>
    <other_name>Lansoprazole/Clarithromycin/Amoxicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  H. pylori-positive at screening&#xD;
&#xD;
          -  Complain of gastric discomfort symptom&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having received prior therapy for eradication of H. pylori&#xD;
&#xD;
          -  Prior use of proton pump inhibitors (PPIs), H2 receptor blockers, at a full dosage&#xD;
             within 14 days&#xD;
&#xD;
          -  Prior use of H. pylori eradication effective antibiotics, bismuth within 14 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Chan Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

